Innoveren Scientific (Innoveren Scientific) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is Innoveren Scientific Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Innoveren Scientific is: No Data: Cannot be evaluated.

Competitive Comparison of Innoveren Scientific's Risk Assessment

For the Biotechnology subindustry, Innoveren Scientific's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innoveren Scientific's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoveren Scientific's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Innoveren Scientific's Risk Assessment falls into.

Innoveren Scientific (OTCPK:IVRN) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Innoveren Scientific Risk Assessment Related Terms

Thank you for viewing the detailed overview of Innoveren Scientific's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Innoveren Scientific (Innoveren Scientific) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoveren Scientific Inc (OTCPK:IVRN) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

2202 N West Shore Boulevard, Suite 200, Tampa, FL, USA, 33607

Website

https://www.hcyte.com

Innoveren Scientific Inc Formerly H-CYTE Inc is a hybrid biopharmaceutical company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders. It has two divisions: the Healthcare Medical Biosciences Division (which includes the Infusion Vertical and the Biologics Vertical) and the DenerveX medical device division.

Executives

Fwhc Holdings, Llc	10 percent owner	1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Hoa Capital Llc	10 percent owner	1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Farrior J Rex Iii	10 percent owner	1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Fwhc Bridge Friends, Llc	10 percent owner	1306 W KENNEDY BOULEVARD, TAMPA FL 33606
Raymond Monteleone	director	201 E KENNEDY BLVD, STE 700, TAMPA FL 33602
Jeremy Daniel	officer: Chief Financial Officer	201 E KENNEDY AVE, STE 700, TAMPA FL 33602
Robert Smith Greif	officer: President and C.E.O.	19 MAY STREET, NEEDHAM MA 02492
Cfrs Investments, Llc	10 percent owner	2903 W VILLA ROSA PARK, TAMPA FL 33611
Frederick J Lynch	10 percent owner	C/O MASONITE INTERNATIONAL CORPORATION, 201 NORTH FRANKLIN ST., SUITE 300, TAMPA FL 33602
Fwhc Bridge, Llc	10 percent owner	334 EAST LAKE ROAD, SUITE 176, PALM HARBOT FL 34685
Todd R Wagner	10 percent owner	3385 OLD KEYSTONE ROAD, TARPON SPRINGS FL 34688
Michael Yurkowsky	director	2380 OLD MILTON PARKWAY, ALPHARETTA GA 30009
William E Horne	director, officer: Chief Executive Officer	201 EAST KENNEDY BLVD, SUITE 700, TAMPA FL 33602
Jon Mogford	director	714 PLUM HOLLOW DRIVE, COLLEGE STATION TX 77845
John C Thomas	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615